AISAP Cardio vs iPredict Eye Screening

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AISAP Cardio

by Aisap

iPredict Eye Screening

by iHealthScreen

AI Verdict

AISAP Cardio focuses on AI-powered point-of-care ultrasound for comprehensive cardiac diagnostic assessments, including valvular pathologies and ventricular measurements. iPredict Eye Screening, while also using AI and offering some systemic disease risk prediction, primarily targets early detection of retinal diseases like AMD, DR, and Glaucoma through retinal imaging. While both leverage AI for early disease detection and integrate with EHRs, their core diagnostic modalities and primary medical specialties are distinct.

Choose AISAP Cardio if…

Choose AISAP Cardio if your priority is rapid, comprehensive cardiac diagnostic assessments at the point of care, particularly for early detection of structural heart disease and heart failure. This tool is ideal for emergency medicine or cardiology settings requiring immediate, AI-powered interpretation of cardiac ultrasounds and automated report generation for valvular pathologies and ventricular function.

View AISAP Cardio →

Choose iPredict Eye Screening if…

Choose iPredict Eye Screening if your primary need is an AI-powered screening tool for multiple ocular diseases like age-related macular degeneration, diabetic retinopathy, and glaucoma, especially in primary care or telemedicine settings. This platform is also beneficial for integrating risk prediction for systemic diseases such as stroke and heart attack, offering fast, non-invasive screening with high accuracy.

View iPredict Eye Screening →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AISAP Cardio	iPredict Eye Screening
Pricing	Not publicly available	Contact for pricing
Deployment	Cloud-based SaaS platform	Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps.
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

iPredict Eye Screening

iPredict Eye Screening emphasizes ease of use with claims of a non-invasive, advanced touchscreen interface, and tests completed in less than 5 minutes with reports in under 60 seconds. AISAP Cardio also highlights rapid results and integration into workflows, but iPredict's specific mentions of a touchscreen and quick test/report times suggest a slightly more streamlined user experience for its intended screening purpose.

Clinical Value

AISAP Cardio

AISAP Cardio provides comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure, with validation in multi-national, multi-site clinical trials. While iPredict Eye Screening offers screening for multiple conditions (AMD, DR, Glaucoma) and systemic disease risk prediction, AISAP Cardio's depth in cardiac diagnostics and strong clinical validation for a critical and complex organ system gives it an edge in clinical value.

Pricing & Value

iPredict Eye Screening

iPredict Eye Screening offers transparent pricing details, estimating $10-$20 per patient screening, which is 20%-40% of Medicare/commercial payor reimbursement. AISAP Cardio's pricing is not publicly available, making it difficult to assess its value proposition.

Enterprise Readiness

AISAP Cardio

AISAP Cardio is a vendor-agnostic, scalable solution that seamlessly integrates with existing clinical workflows, EHR/EMR, and PACS systems, and is in use across health systems, hospitals, and clinics worldwide. While iPredict also integrates with EHR and telemedicine services, AISAP's explicit mention of PACS integration and broader deployment in diverse healthcare settings suggests a more robust enterprise readiness.

Innovation

Tie

Both tools demonstrate significant innovation in their respective fields. AISAP Cardio is the first company to secure FDA clearance in the CADx pathway for comprehensive diagnosis of structural heart diseases using POCUS, leveraging AI for rapid, expert-level cardiac assessments. iPredict Eye Screening offers AI-powered screening for multiple retinal diseases and risk prediction for systemic diseases, with a focus on making early detection widely accessible. Both are pushing boundaries in AI-powered diagnostics.

Support & Docs

Tie

Neither structured facts nor web searches provided specific details on the depth or accessibility of support and documentation for either AISAP Cardio or iPredict Eye Screening. Therefore, based on the available information, it is not possible to definitively pick a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AISAP Cardio	iPredict Eye Screening
Product Name	AISAP Cardio	iPredict Eye Screening
Company	Aisap	iHealthScreen
Description	FDA-cleared, AI-powered point-of-care ultrasound (POCUS) software platform that provides rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside.	FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services.
Key Specialties	Cardiology, Emergency Medicine, Radiology	Family Medicine, Internal Medicine, Ophthalmology

Videos

Demos, reviews, and walkthroughs featuring AISAP Cardio and iPredict Eye Screening.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How deeply do these tools integrate with existing EHR and PACS systems, and what is the workflow impact for my clinical staff?

AISAP Cardio is designed for seamless integration with existing EHR/EMR and PACS systems, aiming to provide rapid, comprehensive cardiac diagnostic assessments at the bedside and generate reports in minutes. This integration is intended to enhance decision-making for various physicians and improve workflow efficiency. iPredict Eye Screening also integrates with EHR and telemedicine services, and the entire screening process, including image capture and automated report generation, can be completed within 5 minutes, with results available in under 60 seconds.

What are the reported accuracy and sensitivity rates for each tool in detecting relevant clinical conditions?

AISAP Cardio has demonstrated a 93% sensitivity and 93% specificity for significant major valve diseases, and enables non-cardiologists to interpret echocardiograms as accurately as expert cardiologists. iPredict Eye Screening reports an average accuracy of approximately 95%. Specifically, for Age-related Macular Degeneration (AMD), iPredict-AMD achieved a sensitivity of 86.86% and a specificity of 94.13%. For Diabetic Retinopathy (DR), studies have shown iPredict with 86.9% sensitivity and 94.1% specificity. For glaucoma suspect, iPredict achieved 89.67% accuracy with 83.33% sensitivity and 93.89% specificity.

What is the typical learning curve for physicians and clinical staff to become proficient with each tool?

For AISAP Cardio, it takes a few hours to train a physician, though achieving full proficiency might require performing between 30-50 scans. The system provides real-time feedback to help clinicians improve image quality. iPredict Eye Screening requires minimal training, with proficiency achievable in less than one hour to operate the models.

What kind of clinical support and customer references are available to validate the real-world effectiveness and usability of these tools?

AISAP Cardio has been validated through extensive clinical trials at renowned institutions such as Mass General Brigham, Mayo Clinic, and Sheba Medical Center, with studies showing improved clinician accuracy and changes in care pathways. Customer feedback indicates it has been a 'game-changer' in primary care and cardiovascular offices, improving efficiency and decision-making. iHealthScreen's iPredict system has been used in clinical settings to screen over 10,000 people for DR, AMD, and glaucoma in Australia, the UAE, and Bangladesh.

What audit-trail capabilities do these tools offer to track usage, interpretations, and changes for regulatory and quality assurance purposes?

AISAP Cardio automatically generates analyses, interpretations, and reports, and integrates with existing EHR/EMR and PACS systems, which would typically facilitate audit trails within those integrated systems. The platform also sends images and reports to the healthcare organization's digital infrastructure for future reference. iPredict Eye Screening provides fully automated reports, which, when integrated with EHR solutions, would contribute to an audit trail.

How do these tools facilitate multi-site rollout and management, especially for larger healthcare systems or those with remote clinics?

AISAP Cardio is a vendor-agnostic and scalable solution designed for seamless integration into various healthcare environments, including existing EHR/EMR and PACS systems, making it adaptable for multi-site deployment. It is being deployed in initiatives to bring expert-level cardiac diagnostics to underserved communities and rural locations, demonstrating its scalability for widespread use. iPredict Eye Screening is also cloud-based and accessible in primary care settings, clinics, hospitals, and online for telemedicine, suggesting suitability for multi-site rollouts and remote access.